Skip to main content

Advertisement

SpringerLink
Log in

Allergic bronchopulmonary aspergillosis: what’s known and what’s new

  • Bronchiectasis (G Tino, Section Editor)
  • Published:
Current Pulmonology Reports Aims and scope Submit manuscript

Abstract

Recent investigations concerning ABPA have expanded our understanding of the disease. The diagnostic criteria for ABPA are not standardized. Novel analytic techniques have compared the varied diagnostic criteria even in the absence of a gold standard. Additional analyses have determined the sensitivity and specificity of various parameters for the diagnosis of ABPA, as well as combinations of several parameters that have extremely high specificity and sensitivity. New biomarkers have also been proposed to diagnosis and monitor ABPA. Research concerning specific antigenic triggers of the Th2 response and HLA polymorphisms in ABPA has led to relevant new insights concerning the immunopathogenesis of the disease. Treatment trials have further clarified the optimal corticosteroid dosing regimen and the role of antifungal therapy and anti-IgE therapy for the treatment of ABPA. We suspect that such research efforts will continue to accelerate our understanding of this disease that will benefit ABPA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Bains SN, Judson MA. Allergic bronchopulmonary aspergillosis. Clin Chest Med. 2012;33(2):265–81.

    Article  PubMed  Google Scholar 

  2. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009;135(3):805–26.

    Article  PubMed  Google Scholar 

  3. Agarwal R, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A, Jindal SK. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest. 2007;132(4):1183–90.

    Article  PubMed  Google Scholar 

  4. Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol. 2012;129(2):280–91. quiz 292-283.

    Article  PubMed  Google Scholar 

  5. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37 Suppl 3:S225–64.

    Article  PubMed  Google Scholar 

  6. Agarwal R, Maskey D, Aggarwal AN, et al. Diagnostic performance of various tests and criteria employed in allergic bronchopulmonary aspergillosis: a latent class analysis. PLoS One. 2013;8(4):e61105. Various clinical parameters were examined in 372 consecutive asthma patients to determine their sensitivity and specificity for the diagnosis of ABPA. A. fumigatus specific IgE levels and high-attenuation mucus on chest CT imaging were the most sensitive and specific parameters for the diagnosis of APBA.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977;86(4):405–14.

    Article  CAS  PubMed  Google Scholar 

  8. Greenberger PA, Bush RK, Demain JG, Luong A, Slavin RG, Knutsen AP. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2014;2(6):703–8.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Nascimento MC, de Souza VA, Sumita LM, et al. Comparative study of Kaposi’s sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis. J Clin Microbiol. 2007;45(3):715–20.

    Article  CAS  PubMed  Google Scholar 

  10. Rindskopf D, Rindskopf W. The value of latent class analysis in medical diagnosis. Stat Med. 1986;5(1):21–7.

    Article  CAS  PubMed  Google Scholar 

  11. Agarwal R, Aggarwal AN, Garg M, Saikia B, Chakrabarti A. Cut-off values of serum IgE (total and A. fumigatus-specific) and eosinophil count in differentiating allergic bronchopulmonary aspergillosis from asthma. Mycoses. 2014;57(11):659–63.

    Article  CAS  PubMed  Google Scholar 

  12. Dumollard C, Bailly S, Perriot S, et al. Prospective evaluation of a new Aspergillus IgG EIA kit for the diagnosis of chronic and allergic pulmonary aspergillosis. J Clin Microbiol. 2016;54(5):1236–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kaur M, Sudan DS. Allergic bronchopulmonary aspergillosis (ABPA)—the high resolution computed tomography (HRCT) chest imaging scenario. J Clin Diagn Res JCDR. 2014;8(6):Rc05–7. The high resolution chest CT findings were described in 110 consecutive patients with ABPA.

    PubMed  Google Scholar 

  14. Phuyal S, Garg MK, Agarwal R, et al. High-attenuation mucus impaction in patients with allergic bronchopulmonary aspergillosis: objective criteria on high-resolution computed tomography and correlation with serologic parameters. Curr Probl Diagn Radiol. 2016;45(3):168–73.

    Article  PubMed  Google Scholar 

  15. Tanimoto H, Fukutomi Y, Yasueda H, et al. Molecular-based allergy diagnosis of allergic bronchopulmonary aspergillosis in Aspergillus fumigatus-sensitized Japanese patients. Clin Exp Allergy. 2015;45(12):1790–800.

    Article  CAS  PubMed  Google Scholar 

  16. Gernez Y, Dunn CE, Everson C, et al. Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. J Cyst Fibros. 2012;11(6):502–10. A test of basophil activation, CD203c levels determined by flow cytometry, was measured in 20 patients with concomitant ABPA and CF, CF with A. fumigatus colonization but without ABPA, and CF patients without ABPA or A. fumigatus colonization. This basophil activation test reliably distinguished the concomitant ABPA and CF patients from the other two groups.

    Article  CAS  PubMed  Google Scholar 

  17. Gernez Y, Walters J, Mirkovic B, et al. Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J. 2016;47(1):177–85.

    Article  CAS  PubMed  Google Scholar 

  18. Katelari A, Tzanoudaki M, Noni M, et al. The role of basophil activation test in allergic bronchopulmonary aspergillosis and Aspergillus fumigatus sensitization in cystic fibrosis patients. J Cyst Fibros. 2016;15(5):587–96.

    Article  PubMed  Google Scholar 

  19. Rocchi S, Richaud-Thiriez B, Barrera C, et al. Replies to “Is the home environment an important factor in the occurrence of fungal events in cystic fibrosis?”. J Cyst Fibros. 2016;15(2):e17–8.

    Article  PubMed  Google Scholar 

  20. Vernon DR, Allan F. Environmental factors in allergic bronchopulmonary aspergillosis. Clin Allergy. 1980;10(2):217–27.

    Article  CAS  PubMed  Google Scholar 

  21. Sharpe R, Thornton CR, Osborne NJ. Modifiable factors governing indoor fungal diversity and risk of asthma. Clin Exp Allergy. 2014;44(5):631–41.

    Article  CAS  PubMed  Google Scholar 

  22. Agarwal R, Devi D, Gupta D, Chakrabarti A. A questionnaire-based study on the role of environmental factors in allergic bronchopulmonary aspergillosis. Lung India. 2014;31(3):232–6.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 1984;74(5):645–53.

    Article  CAS  PubMed  Google Scholar 

  24. Greenberger PA, Smith LJ, Hsu CC, Roberts M, Liotta JL. Analysis of bronchoalveolar lavage in allergic bronchopulmonary aspergillosis: divergent responses of antigen-specific antibodies and total IgE. J Allergy Clin Immunol. 1988;82(2):164–70.

    Article  CAS  PubMed  Google Scholar 

  25. Becker KL, Gresnigt MS, Smeekens SP, et al. Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients. Clin Exp Allergy. 2015;45(2):423–37.

    Article  CAS  PubMed  Google Scholar 

  26. Jolink H, de Boer R, Willems LN, van Dissel JT, Falkenburg JH, Heemskerk MH. T helper 2 response in allergic bronchopulmonary aspergillosis is not driven by specific Aspergillus antigens. Allergy. 2015;70(10):1336–9.

    Article  CAS  PubMed  Google Scholar 

  27. Muro M, Mondejar-Lopez P, Moya-Quiles MR, et al. HLA-DRB1 and HLA-DQB1 genes on susceptibility to and protection from allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Microbiol Immunol. 2013;57(3):193–7.

    Article  CAS  PubMed  Google Scholar 

  28. Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med. 1986;146(5):916–8.

    Article  CAS  PubMed  Google Scholar 

  29. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110(5):685–92.

    Article  PubMed  Google Scholar 

  30. Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest. 2006;130(2):442–8.

    Article  PubMed  Google Scholar 

  31. Thomson JM, Wesley A, Byrnes CA, Nixon GM. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol. 2006;41(2):164–70.

    Article  PubMed  Google Scholar 

  32. Cohen-Cymberknoh M, Blau H, Shoseyov D, et al. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cyst Fibros. 2009;8(4):253–7.

    Article  CAS  PubMed  Google Scholar 

  33. Singh Sehgal I, Agarwal R. Pulse methylprednisolone in allergic bronchopulmonary aspergillosis exacerbations. Eur Respir Rev. 2014;23(131):149–52.

    Article  PubMed  Google Scholar 

  34. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000;342(11):756–62.

    Article  CAS  PubMed  Google Scholar 

  35. Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 2003;111(5):952–7.

    Article  CAS  PubMed  Google Scholar 

  36. Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma. 2012;49(4):423–33.

    Article  CAS  PubMed  Google Scholar 

  37. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros. 2005;4(4):215–20.

    Article  CAS  PubMed  Google Scholar 

  38. Glackin L, Leen G, Elnazir B, Greally P. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J. 2009;102(1):29.

    CAS  PubMed  Google Scholar 

  39. Agarwal R, Aggarwal AN, Dhooria S, et al. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2016;47(2):490–8. An open label trial of comparing a high corticosteroid dose and medium corticosteroid dose for the initial treatment and maintenance of ABPA. Although the composite response rates were greater in the high dose than the medium dose group, improvement in lung function and time to first exacerbation were similar. Corticosteroid side effects were significantly higher in the high dose group. The authors recommended the medium dose corticosteroid regimen over the high dose regimen on the basis of these data.

    Article  PubMed  Google Scholar 

  40. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.

    Article  PubMed  Google Scholar 

  41. Moreira AS, Silva D, Ferreira AR, Delgado L. Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: a systematic review. Clin Exp Allergy. 2014;44(10):1210–27. Systematic review of antifungal therapy for ABPA in CF patients.

    Article  CAS  PubMed  Google Scholar 

  42. Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2014;11:Cd002204. Cochrane database systematic review of antifungal therapy for ABPA in CF patients.

    Google Scholar 

  43. Chishimba L, Langridge P, Powell G, Niven RM, Denning DW. Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). J Asthma. 2015;52(3):289–95.

    Article  CAS  PubMed  Google Scholar 

  44. Ram B, Aggarwal AN, Dhooria S, et al. A pilot randomized trial of nebulized amphotericin in patients with allergic bronchopulmonary aspergillosis. J Asthma. 2016;53(5):517–24.

    Article  CAS  PubMed  Google Scholar 

  45. Rundfeldt C, Steckel H, Scherliess H, Wyska E, Wlaz P. Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. Eur J Pharm Biopharm. 2013;83(1):44-–53.

    Article  CAS  PubMed  Google Scholar 

  46. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax. 2007;62(3):276–7.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol. 2008;43(6):607–10.

    Article  PubMed  Google Scholar 

  48. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol. 2008;43(12):1249–51.

    Article  PubMed  Google Scholar 

  49. Lehmann S, Pfannenstiel C, Friedrichs F, Kroger K, Wagner N, Tenbrock K. Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ther Adv Respir Dis. 2014;8(5):141–9.

    Article  CAS  PubMed  Google Scholar 

  50. Aydin O, Sozener ZC, Soyyigit S, et al. Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center’s experience with 14 cases. Allergy Asthma Proc. 2015;36(6):493–500.

    Article  PubMed  Google Scholar 

  51. Voskamp AL, Gillman A, Symons K, et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol In Pract. 2015;3(2):192–9.

    Article  Google Scholar 

  52. Wong R, Wong M, Robinson PD, Fitzgerald DA. Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis. Paediatr Respir Rev. 2013;14(1):22–4.

    Article  PubMed  Google Scholar 

  53. Emiralioglu N, Dogru D, Tugcu GD, Yalcin E, Kiper N, Ozcelik U. Omalizumab treatment for allergic bronchopulmonary aspergillosis in cystic fibrosis. Ann Pharmacother. 2016;50(3):188–93.

    Article  CAS  PubMed  Google Scholar 

  54. Jat KR, Walia DK, Khairwa A. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2015;11:Cd010288. Cochrane database systematic review of anti-IgE therapy for ABPA in CF patients.

    Google Scholar 

  55. Hall WB, Sparks AA, Aris RM. Vitamin D deficiency in cystic fibrosis. Int J Endocrinol. 2010;2010:218691.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kreindler JL, Steele C, Nguyen N, et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest. 2010;120(9):3242–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Nguyen NL, Pilewski JM, Celedon JC, et al. Vitamin D supplementation decreases Aspergillus fumigatus specific Th2 responses in CF patients with aspergillus sensitization: a phase one open-label study. 2015; 1. doi:10.1186/s40733-015-0003-5.

  58. Ricketti AJ, Greenberger PA, Patterson R. Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 1984;74(1):68–71.

    Article  CAS  PubMed  Google Scholar 

  59. Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis. Respir Med. 2010;104(2):204–10.

    Article  PubMed  Google Scholar 

  60. Agarwal R, Aggarwal AN, Sehgal IS, Dhooria S, Behera D, Chakrabarti A. Utility of IgE (total and Aspergillus fumigatus specific) in monitoring for response and exacerbations in allergic bronchopulmonary aspergillosis. Mycoses. 2016;59(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  61. Natarajan S, Subramanian P. Allergic bronchopulmonary aspergillosis: a clinical review of 24 patients: are we right in frequent serologic monitoring? Ann Thorac Med. 2014;9(4):216–20.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Albany Medical College, MC-91; 47 New Scotland Avenue, Albany, NY, 12208, USA

    Marc A. Judson

Authors
  1. Marc A. Judson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc A. Judson.

Ethics declarations

Conflict of Interest

Marc Judson is a consultant for Biogen and Mallinckrodt. He has received institutional grant support from Mallinckrodt and the Foundation for Sarcoidosis Research.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Bronchiectasis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Judson, M.A. Allergic bronchopulmonary aspergillosis: what’s known and what’s new. Curr Pulmonol Rep 5, 177–183 (2016). https://doi.org/10.1007/s13665-016-0155-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13665-016-0155-7

Keywords

Search

Navigation